Drug Trial Radar · NCT07023835
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Sep 17, 2025
Primary completion
Mar 2028
Study completion Oct 2028
Sponsor
- Lead sponsor
- Zydus Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Conditions
- Amyotrophic Lateral Sclerosis (ALS)
Interventions
50 mg UsnoflastDrug
50 mg Usnoflast (50 mg Usnoflast capsules and matching placebo of 25 mg capsule)
75 mg UsnoflastDrug
75 mg Usnoflast (25 mg + 50 mg Usnoflast capsules)
PlaceboDrug
Matching placebo of 25 mg and 50 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of Usnoflast versus placebo assessed using the revised ALSFRS-R total scoreTime frame: From baseline through Week 36
- Efficacy of Usnoflast versus placebo assessed using the survivalTime frame: From baseline through Week 36
- Effect of Usnoflast versus placebo on survival in Open label extension phaseTime frame: From baseline through Week 16
- Number of participants with treatment emergent adverse events in open label extensionTime frame: From baseline through Week 16
- Number of participants with Serious adverse events in open label extensionTime frame: From baseline through Week 16
Locations
49 sites in 12 countries. Site status is shown where the registry gives one.
Zydus US015
La Jolla, California · Recruiting
Zydus US008
Orange, California · Not yet recruiting
Zydus US013
San Francisco, California · Recruiting
Zydus US005
New Britain, Connecticut · Recruiting
Zydus US012
Tampa, Florida · Recruiting
Zydus US007
Atlanta, Georgia · Recruiting
Zydus US010
Boston, Massachusetts · Recruiting
Zydus US006
Detroit, Michigan · Recruiting
Zydus US014
Lincoln, Nebraska · Recruiting
Zydus US003
Winston-Salem, North Carolina · Recruiting
Zydus US009
Pittsburgh, Pennsylvania · Recruiting
Zydus US001
Dallas, Texas · Recruiting
Zydus US002
Houston, Texas · Recruiting
Zydus US004
Richmond, Virginia · Recruiting
Zydus US011
Seattle, Washington · Recruiting
Zydus 202
Southport, Australia · Not yet recruiting
Zydus 200
Caulfield South, Australia, Australia · Recruiting
Zydus 201
Sydney, New South Wales, Australia · Recruiting
Zydus 110
Leuven, Belgium, Belgium · Not yet recruiting
Zydus 101
Toronto, Ontario, Canada · Not yet recruiting
Zydus 100
Québec, Quebec, Canada · Active not recruiting
Zydus 124
Clermont-Ferrand, France, France · Not yet recruiting
Zydus 122
Limoges, France, France · Not yet recruiting
Zydus 123
Montpellier, France, France · Recruiting
Zydus 125
Nice, France, France · Recruiting
Zydus 120
Paris, France, France · Recruiting
Zydus 121
Tours, France, France · Recruiting
Zydus 130
Dresden, Germany, Germany · Not yet recruiting
Zydus 133
Hanover, Germany, Germany · Not yet recruiting
Zydus 134
Jena, Germany, Germany · Not yet recruiting
Zydus 131
Lübeck, Germany, Germany · Not yet recruiting
Zydus 132
Rostock, Germany, Germany · Not yet recruiting
Zydus 135
Ulm, Germany, Germany · Not yet recruiting
Zydus 140
Dublin, Ireland, Ireland · Not yet recruiting
Zydus 150
Brescia, Italy · Recruiting
Zydus 154
Genova, Italy, Italy · Not yet recruiting
Zydus 153
Milan, Italy, Italy · Not yet recruiting
Zydus 151
Modena, Italy, Italy · Not yet recruiting
Zydus 152
Naples, Italy, Italy · Recruiting
Zydus 160
Utrecht, Netherlands, Netherlands · Recruiting
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.